The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Radioactive iodine therapy
Abstract
PURPOSE OF REVIEW: Review of the management decisions that must be made by the endocrinologist during the use of radioactive iodine (RAI) therapy of hyperthyroidism and differentiated thyroid cancer. RECENT FINDINGS: Since the 1940s radioactive (131)I (RAI) therapy has been a major component of the treatment of hyperthyroidism and differentiated thyroid cancer. RAI is the most common definitive treatment of hyperthyroidism. Pretherapy decisions including use of antithyroid medication and low-iodine diet will be discussed with the relevant supportive literature. The method of semi-quantitative calculation used for RAI treatment of hyperthyroidism will be described. Evidence-based guideline for the management of differentiated thyroid cancer by the American Thyroid Association, new drug development and recent randomized controlled trials have changed current practice of how RAI is used for remnant ablation and adjuvant therapy of differentiated thyroid cancer. SUMMARY: RAI is a common tool for the endocrinologist in the management of hyperthyroidism and differentiated thyroid cancer. Review of the management decisions and practice of RAI therapy will educate the endocrinologist of the literature supporting current RAI use in hyperthyroidism and new developments in limiting the radiation exposure to the patients with differentiated thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationBahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Bardet, S., Leenhardt, L., Bastie, D., Schvartz, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108586 · Cited by 684
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
Mallick, U., Harmer, C., Yap, B., Wadsley, J., Clarke, S., Moss, L., Nicol, A., Clark, P. M., Farnell, K., McCready, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109589 · Cited by 615
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Relation between Effective Radiation Dose and Outcome of Radioiodine Therapy for Thyroid Cancer
Maxon, H. R., Thomas, S. R., Hertzberg, V. S., Kereiakes, J. G., Chen, I.-W., Sperling, M. I., & Saenger, E. L. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310203091601 · Cited by 503
Brown, A. P., Chen, J., Hitchcock, Y. J., Szabo, A., Shrieve, D. C., & Tward, J. D. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1154 · Cited by 384
Hänscheid, H., Laßmann, M., Luster, M., Thomas, S. R., Pacini, F., Ceccarelli, C., Ladenson, P. W., Wahl, R. L., Schlumberger, M. J., Ricard, M., et al. (2006) · PubMed · Cited by 329
Bartalena, L., Marcocci, C., Bogazzi, F., Panicucci, M., Lepri, A., & Pinchera, A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212001 · Cited by 318
Radioiodine Therapy for Hyperthyroidism
Ross, D. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmct1007101 · Cited by 284
HERTZ, S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870190005002 · Cited by 263
High Dose 131I Therapy for the Treatment of Hyperthyroidism Caused by Graves' Disease
Alexander, E. K. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1073 · Cited by 251
Sources of Dietary Iodine: Bread, Cows’ Milk, and Infant Formula in the Boston Area
Pearce, E. N., Pino, S., He, X., Bazrafshan, H. R., Lee, S. L., & Braverman, L. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032002 · Cited by 241
Self-citationSisson, T. A. T. A. T., Freitas, J., McDougall, I. R., Dauer, L. T., Hurley, J. R., Brierley, J. D., Edinboro, C. H., Rosenthal, D., Thomas, M. J., Wexler, J. A., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0403 · Cited by 234
Bahn, R. S., Burch, H. S., Cooper, D. S., Garber, J. R., Greenlee, C. M., Klein, I. L., Laurberg, P., McDougall, I. R., Rivkees, S. A., Ross, D., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0169 · Cited by 223
Tuttle, R. M., Leboeuf, R., Robbins, R. J., Qualey, R., Pentlow, K. S., Larson, S. M., & Chan, C.-Y. (2006) · PubMed · Cited by 207
Walter, M. A., Briel, M., Christ-Crain, M., Bonnema, S. J., Connell, J., Cooper, D. S., Bucher, H. C., Müller-Brand, J., & Müller, B. (2007) · BMJ · doi:10.1136/bmj.39114.670150.be · Cited by 202
The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer
Van Nostrand, D. (2009) · Thyroid · doi:10.1089/thy.2009.1611 · Cited by 195
Pilli, T., Brianzoni, E., Capoccetti, F., Castagna, M. G., Fattori, S., Poggiu, A., Rossi, G., Ferretti, F., Guarino, E., Burroni, L., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0225 · Cited by 176
PETERS, H., FISCHER, C., BOGNER, U., REINERS, C., & SCHLEUSENER, H. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01547.x · Cited by 174
Nostrand, D. V., Neutze, J. A., & Atkins, F. B. (1986) · PubMed · Cited by 155
THE TREATMENT OF HYPERTHYROIDISM WITH RADIOACTIVE IODINE
Chapman, E. M., & EVANS, R. D. (1946) · JAMA · doi:10.1001/jama.1946.02870190010003 · Cited by 150
Chiovato, L., Fiore, E., Vitti, P., Rocchi, R., Rago, T., Dokić, D., Latrofa, F., Mammoli, C., Lippi, F., Ceccarelli, C., et al. (1998) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem.83.1.4492 · Cited by 146
Lai, A., Sassi, L., Compri, E., Marino, F., Sivelli, P., Piantanida, E., Tanda, M. L., & Bartalena, L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2130 · Cited by 129
Comparison of Radioiodine with Radioiodine plus Lithium in the Treatment of Graves' Hyperthyroidism
Bogazzi, F., Bartalena, L., Brogioni, S., Scarcello, G., Burelli, A., Campomori, A., Manetti, L., Rossi, G., Pinchera, A., & Martino, E. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5446 · Cited by 115
Burch, H. B., Solomon, B. L., Cooper, D. S., Ferguson, P., Walpert, N., & Howard, R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7639 · Cited by 110
Prevention of Graves’ ophthalmopathy
Bartalena, L. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.09.004 · Cited by 103
de Rooij, A., Vandenbroucke, J. P., Smit, J. W. A., Stokkel, M. P. M., & Dekkers, O. M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0286 · Cited by 102 · cited 1×
“Calculated dose and dosimetry have been shown by meta-analysis to be equally effective [27].”
BackgroundTala, H., Robbins, R. J., Fagin, J. A., Larson, S. M., & Tuttle, R. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0305 · Cited by 102
Risk-Adapted Management of Thyroid Cancer
Tuttle, R. M. (2008) · Endocrine Practice · doi:10.4158/ep.14.6.764 · Cited by 99
Elisei, R., Schlumberger, M. J., Driedger, A. A., Reiners, C., Kloos, R. T., Sherman, S. I., Haugen, B. R., Corone, C., Molinaro, E., Grasso, L., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0869 · Cited by 92
Sawka, A. M., Ibrahim-zada, I., Galacgac, P., Tsang, R. W. C., Brierley, J. D., Ezzat, S., & Goldstein, D. P. (2010) · Thyroid · doi:10.1089/thy.2010.0055 · Cited by 89
Bogazzi, F., Giovannetti, C., Fessehatsion, R., Tanda, M. L., Campomori, A., Compri, E., Rossi, G., Ceccarelli, C., Vitti, P., Pinchera, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1655 · Cited by 88 · cited 1×
“The difference was especially marked in hyperthyroid patients with large goiters more than 40 g [32,33].”
BackgroundRisk of Second Primary Malignancies in Women with Papillary Thyroid Cancer
Canchola, A. J., Horn‐Ross, P. L., & Purdie, D. M. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj072 · Cited by 80
dos Santos, R. B., Romaldini, J. H., & Ward, L. S. (2004) · Thyroid · doi:10.1089/1050725041517093 · Cited by 72
Chiovato, L., Santini, F., Vitti, P., Bendinelli, G., & Pinchera, A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02516.x · Cited by 71
Liu, Y. Y., van der Pluijm, G., Karperien, M., Stokkel, M. P. M., Pereira, A. M., Morreau, J., Kievit, J., Romijn, J. A., & Smit, J. W. A. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02515.x · Cited by 68
Tuttle, R. M., Lopez, N., Leboeuf, R., Minkowitz, S. M., Grewal, R. K., Brokhin, M., Omry, G., & Larson, S. M. (2010) · Thyroid · doi:10.1089/thy.2009.0401 · Cited by 65
Individualized dosimetry in the management of metastatic differentiated thyroid cancer.
Chiesa, C., Castellani, M. R., Vellani, C., Orunesu, E., Negri, A., Azzeroni, R., Botta, F., Maccauro, M., Aliberti, G., Seregni, E. C., et al. (2009) · PubMed · Cited by 58
Bonnema, S. J., Bennedbæk, F. N., Veje, A., Marving, J., & Hegedűs, L. D. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0226 · Cited by 56
Graf, H., Fast, S., Pacini, F., Pinchera, A., Leung, A. M., Vaisman, M., Reiners, C., Wémeau, J.-L., Huysmans, D. A., Harper, W., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1193 · Cited by 54
Fast, S., Hegedűs, L. D., Grupe, P., Nielsen, V. E., Bluhme, C., Bastholt, L., & Bonnema, S. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0634 · Cited by 44
A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter*
Bonnema, S. J., & Hegedűs, L. D. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832ff2e1 · Cited by 39
Kubota, S., Ohye, H., Genichiro, Y. A. N. O., Nishihara, E., Kudo, T., Ito, M., Fukata, S., Amino, N., Kuma, K., & Miyauchi, A. (2006) · Endocrine Journal · doi:10.1507/endocrj.k06-057 · Cited by 27
Kristoffersen, U. S., Hesse, B., Rasmussen, Å. K., & Kjær, A. (2006) · Clinical Physiology and Functional Imaging · doi:10.1111/j.1475-097x.2006.00666.x · Cited by 19
Hennessey, J. V., Parker, J. A., Kennedy, R., & Garber, J. R. (2012) · Thyroid · doi:10.1089/thy.2011.0378 · Cited by 5
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Radiotheranostics: a roadmap for future development
Herrmann, K., Schwaiger, M., Lewis, J. S., Solomon, S. B., McNeil, B. J., Baumann, M., Gambhir, S. S., Hricak, H., & Weissleder, R. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30821-6 · Cited by 327
The Na+/I− Symporter (NIS): Mechanism and Medical Impact
Portulano, C., Paroder-Belenitsky, M., & Carrasco, N. (2014) · Endocrine Reviews · doi:10.1210/er.2012-1036 · Cited by 319
Metadata
- Authors
- Lee, S. L.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2012-10
- Volume
- 19
- Issue
- 5
- Pages
- 420-428
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W2312576106
- Cited by
- 307
- References
- 47
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.